/

Empresas

Bi

No verificado

Biogen Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

59 Comunicados de prensa

Ver todos los comunicados de prensa

11/03/2026

Biotecnología

Medicina Salud Bienestar

Anuncios breves

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Fuente

Editor

1.00

0

05/03/2026

Biotecnología

Medicina Salud Bienestar

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Fuente

Editor

1.00

0

04/03/2026

Biotecnología

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Fuente

Editor

1.00

0

11/02/2026

Biotecnología

Biogen Announces Board Chair Transition

Fuente

Editor

1.00

0

04/02/2026

Biotecnología

Medicina Salud Bienestar

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Fuente

Editor

1.00

0

28/01/2026

Biotecnología

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Fuente

Editor

1.00

0

12/01/2026

Biotecnología

Medicina Salud Bienestar

Anuncios breves

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Fuente

Editor

1.00

0

22/12/2025

Biotecnología

Medicina Salud Bienestar

Anuncios breves

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Fuente

Editor

1.00

0

05/12/2025

Biotecnología

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Fuente

Editor

1.00

0

24/11/2025

Biotecnología

Medicina Salud Bienestar

Gestión empresarial/Administración de Empresas

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0